Gliosarcoma is a rare, Grade 4 brain tumor that is a type of glioblastoma. It has the same WHO classification and urgency as standard glioblastoma, but has two parts - a glial component and a sarcomatous component - that affect how the biopsy is read, what molecular markers show, and which treatment details matter most.
This article compares gliosarcoma and standard glioblastoma across the features that matter most for treatment planning: histology, molecular profile, survival data, and where the two differ.
What is gliosarcoma?
Gliosarcoma is a type of IDH-wildtype glioblastoma recognized by its appearance under the microscope. The WHO classifies it as a Grade 4 glioma, the highest grade, meaning it grows quickly and aggressively. The National Cancer Institute reports that gliosarcoma accounts for approximately 2% of all glioblastoma diagnoses, making it rare among glioblastomas.
The name reflects what the pathologist sees. "Glio" points to glial cells, the brain-support cells that give rise to standard glioblastoma. "Sarcoma" refers to a cancer of connective tissue - a type normally associated with muscle, fat, or bone. In gliosarcoma, both cell types exist in the same tumor mass. This matters for how accurately the diagnosis can be made and how the molecular report should be read.
How gliosarcoma looks different under the microscope
Gliosarcoma has two distinct tissue types in the same tumor. In standard glioblastoma, the biopsy shows predominantly glial cells that stain positive for GFAP (glial fibrillary acidic protein), the standard marker of brain-tumor origin. In gliosarcoma, those GFAP-positive areas exist alongside separate regions of spindle-shaped cells embedded in dense collagen fibers - the sarcomatous component - that stain for a protein called reticulin and are GFAP-negative.
A neuropathologist confirms gliosarcoma when both parts show up in the same biopsy. This creates a specific diagnostic risk: if the biopsy captures only the glial or only the sarcomatous region, the tumor may be classified as standard glioblastoma or as a primary sarcoma, both of which carry different treatment implications. Understanding what your glioblastoma pathology report really means - including whether the biopsy was representative of the full tumor - helps confirm the diagnosis.
How does gliosarcoma compare to standard glioblastoma?
| Feature | Gliosarcoma | IDH-Wildtype Glioblastoma |
|---|---|---|
| Frequency | Approximately 2% of all glioblastoma diagnoses | Most common primary malignant brain tumor in adults |
| Histology | Two parts: alternating glial (GFAP-positive) and sarcomatous (reticulin-positive) regions | Predominantly glial cells; no sarcomatous component |
| IDH Status | IDH-wildtype in nearly all reported cases | IDH-wildtype by definition at WHO Grade 4 |
| MGMT Methylation | Unmethylated in approximately 87-88% of cases; fewer than 12% have methylation | Methylated in a larger proportion; methylation linked to better temozolomide response |
| Standard Treatment | Surgery, chemoradiation (Stupp protocol), adjuvant temozolomide; bevacizumab sometimes added at recurrence | Surgery, Stupp protocol, adjuvant temozolomide; Tumor Treating Fields for eligible patients |
| Extracranial Spread | Reported in some cases - lung, lymph nodes, bone - more often than in typical glioblastoma | Rarely spreads outside the central nervous system |
Sources: NCI Rare Brain and Spine Tumor Program; Giri et al., Neuro-Oncology Advances, 2020; Han et al., Surgical Neurology International, 2018. MGMT figures reflect retrospective series; individual molecular results will differ.
The most clinically significant difference is MGMT methylation. In standard glioblastoma, methylation of the MGMT promoter - a change that silences the gene responsible for repairing chemotherapy-induced DNA damage - is linked to better response to temozolomide. In gliosarcoma, that methylation is uncommon. Published retrospective series consistently report fewer than 12-13% of gliosarcoma tumors as MGMT-methylated, a substantially lower rate than in the broader glioblastoma population. Temozolomide remains part of the standard treatment approach for gliosarcoma, but this molecular reality directly shapes how much benefit the team can realistically expect from it - and makes clinical trials and alternative agents worth discussing early.
Primary gliosarcoma vs secondary gliosarcoma: does the origin matter?
Gliosarcoma can develop in two distinct ways, and this matters clinically.
Primary gliosarcoma is new, not related to a prior tumor. The patient presents with a new mass that already contains both glial and sarcomatous components at the time of first biopsy. Secondary gliosarcoma develops after a prior diagnosis and treatment of standard glioblastoma. The sarcomatous part may develop from prior therapy. Radiation and chemotherapy may favor cells with connective-tissue characteristics. Secondary gliosarcoma typically appears at or near the original tumor site.
Primary and secondary gliosarcomas have very different outcomes. A multicenter analysis of primary and secondary gliosarcomas reported median overall survival of approximately 24.7 months for primary gliosarcoma versus approximately 8.95 months for secondary gliosarcoma - though these figures come from small retrospective cohorts and may not apply to you. If a recurrence diagnosis now carries a gliosarcoma label, it is worth asking your neuro-oncologist directly whether the sarcomatous change is newly identified, how that affects clinical trial eligibility, and whether the treatment plan differs from what would apply to standard glioblastoma recurrence.
What the molecular profile of gliosarcoma reveals
Molecular profiling has confirmed that gliosarcoma is not simply glioblastoma with a different appearance under the microscope. Gliosarcoma has its own molecular profile, with distinguishing features that affect treatment strategy.
IDH status. Gliosarcoma is IDH-wildtype in nearly all published cases - consistent with aggressive gliomas. IDH-mutant gliomas have a better outlook and respond better to treatment; gliosarcoma does not share that more favorable biology.
MGMT promoter methylation. This marker predicts how well a tumor is likely to respond to temozolomide. Retrospective series consistently report that the MGMT promoter is unmethylated in roughly 87-88% of gliosarcoma cases. One analysis found fewer than 12% of gliosarcoma specimens carried a methylated MGMT promoter - a substantially lower proportion than is reported across the broader glioblastoma population. For most gliosarcoma patients, this means the tumor is less likely to respond strongly to temozolomide's core mechanism.
TP53 mutations. Gliosarcoma shows higher rates of TP53 mutations than standard glioblastoma. TP53 encodes a protein that normally acts as a brake on cell division; mutations here remove that control.
Pathway alterations. The PI3K/Akt and RAS/MAPK signaling pathways show changes in gliosarcoma - cellular communication routes that regulate growth and survival. These pathways are under active investigation as therapeutic targets, and they underpin some of the clinical trial interest in this variant.
A complete molecular panel - covering MGMT, IDH, TERT promoter status, CDKN2A/B deletion, and copy number variation analysis - gives the treating team the full picture of what is driving tumor behavior. If your initial pathology report did not include all of these markers, an international pathology second opinion can complete the profiling and confirm the diagnosis on comprehensive molecular grounds.
How gliosarcoma is treated
Because gliosarcoma is rare, no large trials have tested treatment specifically for it. Doctors use standard glioblastoma treatment, changing it when gliosarcoma biology suggests they should.
Standard treatment usually follows these steps:
- Surgery to remove as much tumor as possible. Surgery removes as much of the tumor as possible while protecting neurological function. The sarcomatous component may have clearer edges than standard glioblastoma in some cases, which can assist resection in accessible locations.
- Concurrent chemoradiation. Six weeks of radiation delivered alongside daily low-dose temozolomide - the Stupp protocol framework, developed for standard glioblastoma and applied to gliosarcoma in the absence of gliosarcoma-specific trial data.
- Adjuvant temozolomide. Your doctor typically continues it for up to six cycles after chemoradiation, like standard glioblastoma treatment. Given the low MGMT methylation rate in most gliosarcoma cases, the benefit of this component may be more limited for many patients - but it remains the standard approach.
- Tumor Treating Fields (TTFields). This device-based, non-invasive therapy is approved for newly diagnosed and recurrent glioblastoma. Gliosarcoma is classified as glioblastoma, so TTFields can be used. The article on how Tumor Treating Fields work in glioblastoma covers eligibility and practical details in full.
- Bevacizumab. A drug that stops new blood vessels from forming. Some centers use bevacizumab at recurrence, since both glial and sarcomatous cells tend to develop many blood vessels.
For most gliosarcoma patients, whose tumors are MGMT-unmethylated, limited benefit from temozolomide makes clinical trial enrollment important to discuss early in your treatment course. ClinicalTrials.gov allows filtering by diagnosis and molecular profile to identify currently enrolling studies that may be relevant to your case.
Why a second opinion carries more weight in gliosarcoma
Gliosarcoma's two-part structure creates a diagnostic risk. A biopsy sample that captures only the glial or only the sarcomatous region can result in misclassification as standard glioblastoma or as a primary sarcoma. Both carry different treatment and trial-eligibility implications. Expert pathology review with adequate tissue is the best protection against that error.
A second opinion matters because many centers have limited experience with gliosarcoma. You can have your pathology and MRI reviewed by the Art of Healing Cancer team for an expert assessment - a useful step before starting treatment, especially if coordinating care internationally.
If you are ready to start that process, you can upload your pathology report and MRI scans through the Glioblastoma Center patient journey form and a specialist will follow up with you about next steps.
When to talk to your doctor
Talk to your neuro-oncologist if your pathology report mentions gliosarcoma and a complete molecular panel - covering MGMT, IDH, TERT promoter, and CDKN2A/B status - has not yet been run on the specimen. Ask specifically what proportion of the tumor showed sarcomatous differentiation, whether the diagnosis is primary or secondary gliosarcoma, and whether any clinical trials for rare glioblastoma variants are currently enrolling at your center or at a nearby academic institution. If the gliosarcoma label appears at recurrence, the treatment options may differ meaningfully from your original glioblastoma plan, and an early specialist conversation is worth prioritizing.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.